Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Renal Disease
A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases
- Conditions
- Diabetes Mellitus, Type 2, Renal Disease, Diabetes Mellitus, Metabolic Disease
- Trial name
- NCT04653779
- Testing
- Evogliptin 5mg/Metformin 1000mg
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes, Obesity
Balance System Study in Type 2 Diabetic Patients
To evaluate the safety and performance of the BALANCE System in treating patients who have type 2 diabetes and are overweight. Impact on blood glucose levels, weight loss, blood pressure and other clinical and metabolic…
- Trial name
- NCT00872846
- Testing
- BALANCE System intestinal electrical stimulator
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Beta-Stim Ltd.
Type 2 Diabetes Mellitus
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus…
- Trial name
- NCT01614782
- Testing
- MK-5823
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
The purpose of the study is to collect information on how Tresiba® works in real world patients with Diabetes Mellitus, Type 2 (type 2 diabetes). Participants will get Tresiba® as prescribed by their doctor.
- Trial name
- NCT04315688
- Testing
- insulin degludec
- Where
- 40 sites in Russia
- Volunteers
- 494 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c.
- Trial name
- NCT03230786
- Where
- 30 sites in Czechia, Denmark and 4 more
- Volunteers
- 255 people
- Sponsor
- KeyBioscience AG
Type 2 Diabetes Mellitus
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.
- Trial name
- NCT00822211
- Testing
- Vildagliptin 50 mg bid, Vildagliptin 50 mg qd
- Where
- 17 sites in China
- Volunteers
- 404 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes…
- Trial name
- DM200-101 (NCT00638716)
- Testing
- CJC-1134-PC
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- ConjuChem
Type 2 Diabetes Mellitus
A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus
This is a double-blind, randomised, controlled, two-period crossover phase Ib trial using an individualised standard meal with a fixed nutrient ratio in subjects with type 2 diabetes mellitus to investigate post-prandial blood…
- Trial name
- NCT02562326
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- 2 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 2
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only.
- Trial name
- NCT00518115
- Testing
- Albiglutide (GSK716155) or exenatide
- Where
- 163 sites in United States, Chile and 1 more
- Volunteers
- 361 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.
- Trial name
- NCT01829477
- Testing
- TAK-875, Glimepiride
- Where
- 69 sites in United States, Bulgaria and 5 more
- Volunteers
- 33 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.
- Trial name
- NCT00735501
- Testing
- insulin detemir
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 314 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Diabetes Mellitus, Type 2
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT02848833
- Testing
- JARDIANCE 10mg, JARDIANCE 25mg
- Where
- South Korea
- Volunteers
- 3,368 people
- Sponsor
- Boehringer Ingelheim
Type II Diabetes Mellitus
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
A real-world, point-of-care, randomized, parallel group, open, 6-month clinical study to evaluate if the provision of a digital disease management tool improves glycaemic control in participants with type 2 diabetes mellitus…
- Trial name
- NCT02749435
- Testing
- Use of digital disease management tool in participants with T2DM
- Where
- 14 sites in United Kingdom
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.
- Trial name
- NCT05333835
- Testing
- HR17031 injection, INS068 injection, SHR20004 injection
- Where
- China
- Volunteers
- 455 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
Rationale Rosiglitazone and troglitazone both promote differentiation of pre-adipocytes into adipocytes in subcutaneous, but not omental fat, and reduce gamma glutamyl transferase, a surrogate marker for intra-abdominal and…
- Trial name
- NCT01045590
- Testing
- titration
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.
- Trial name
- NCT01046318
- Testing
- OPC-262
- Where
- 3 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Type 2 Diabetes Mellitus
Insulin Glulisine in Type 2 Diabetes Mellitus
Primary objective: To compare the pharmacodynamics of insulin glulisine and insulin lispro injected subcutaneously before three 500 kcal standard meals during a 12 hour day, in obese subjects with type 2 diabetes.
- Trial name
- NCT00310297
- Testing
- Insulin Glulisine
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.